# Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

> **NCT05044117** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 220 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05044117
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2022-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044117, "Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05044117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*